Use of triplex structure dna in transferring nucleotide sequences
AssigneesInstitut Pasteur, Institut National de la Santéde la Recherche Médicale, Centre National De La Recherche Scientifique
InventorsPierre CHARNEAU, Véronique Zennou, Hüseyin Firat
Life of this patent
Estimating the term…
Abstract
The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.
Claims15
1-40. (canceled)
A recombinant lentiviral vector particle comprising:
- (a) a replication-deficient lentiviral vector comprising a transgene, a lentiviral cis-acting central initiation region, and a lentiviral cis-acting termination region, such that a triplex DNA is formed during reverse transcription,
- wherein the triplex DNA stimulates the nuclear import of the transgene into the nucleus of a cell transduced with said vector, and
- wherein the replication-deficient lentiviral vector does not encode functional Gag, Pol, and Env proteins;
- and
- (b) Gag, Pol, and Env proteins.
Dependencies are inferred from the claim text.